Search research articles
Contact Us
Filters
Showing results (41-50 of 103) with videos related to
Page
of 11
Sort By:
Clinical Pharmacokinetics
|
August 11, 2018
Clinical Pharmacokinetics and Pharmacodynamics of Dabrafenib
Alicja Puszkiel, Gaëlle Noé, Audrey Bellesoeur, et al.
Journal of Pharmaceutical and Biomedical Analysis
|
November 9, 2020
Simultaneous quantification of dabrafenib, hydroxy-dabrafenib and trametinib in human plasma by liquid chromatography-tandem mass spectrometry
David Balakirouchenane, Nihel Khoudour, Sarah Guégan, et al.
Liver International : Official Journal of the International Association for the Study of the Liver
|
July 22, 2009
Deficiency in calcineurin activity in liver transplantation candidates with alcoholic cirrhosis or hepatocellular carcinoma
Benoit Blanchet, Monika Hurtova, Françoise Roudot-Thoraval, et al.
Expert Opinion on Drug Metabolism & Toxicology
|
August 25, 2016
Clinical pharmacology, drug-drug interactions and safety of pazopanib: a review
Pascaline Boudou-Rouquette, Camille Tlemsani, Benoit Blanchet, et al.
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences
|
July 9, 2011
A simple HPLC-UV method for the simultaneous quantification of gefitinib and erlotinib in human plasma
Lionel Faivre, Charline Gomo, Olivier Mir, et al.
Journal of Pharmaceutical and Biomedical Analysis
|
March 3, 2023
LC-MS/MS method for simultaneous quantification of osilodrostat and metyrapone in human plasma from patients treated for Cushing's Syndrome
David Balakirouchenane, Axelle Vasseur, Fidéline Bonnet-Serrano, et al.
Bulletin Du Cancer
|
October 13, 2018
[Issues of oral targeted therapies in daily clinical practice: 5th edition of the congress of pharmacology of anticancer drugs]
Sonia Zaibet, Charles Vauchier, Nihel Khoudour, et al.
Plos One
|
June 6, 2012
Sarcopenia predicts early dose-limiting toxicities and pharmacokinetics of sorafenib in patients with hepatocellular carcinoma
Olivier Mir, Romain Coriat, Benoit Blanchet, et al.
Pharmacological Research
|
July 6, 2016
Plasma vemurafenib exposure and pre-treatment hepatocyte growth factor level are two factors contributing to the early peripheral lymphocytes depletion in BRAF-mutated melanoma patients
Alicja Puszkiel, Mélanie White-Koning, Nicolas Dupin, et al.
Cancers
|
October 14, 2022
Monitoring of Dabrafenib and Trametinib in Serum and Self-Sampled Capillary Blood in Patients with BRAFV600-Mutant Melanoma
Nora Isberner, Anja Gesierich, David Balakirouchenane, et al.
Page
of 11
Search research articles
Search
Showing results (41-50 of 103) with videos related to
Sort By:
Page
of 11
Clinical Pharmacokinetics
|
August 11, 2018
Clinical Pharmacokinetics and Pharmacodynamics of Dabrafenib
Alicja Puszkiel, Gaëlle Noé, Audrey Bellesoeur, et al.
Journal of Pharmaceutical and Biomedical Analysis
|
November 9, 2020
Simultaneous quantification of dabrafenib, hydroxy-dabrafenib and trametinib in human plasma by liquid chromatography-tandem mass spectrometry
David Balakirouchenane, Nihel Khoudour, Sarah Guégan, et al.
Liver International : Official Journal of the International Association for the Study of the Liver
|
July 22, 2009
Deficiency in calcineurin activity in liver transplantation candidates with alcoholic cirrhosis or hepatocellular carcinoma
Benoit Blanchet, Monika Hurtova, Françoise Roudot-Thoraval, et al.
Expert Opinion on Drug Metabolism & Toxicology
|
August 25, 2016
Clinical pharmacology, drug-drug interactions and safety of pazopanib: a review
Pascaline Boudou-Rouquette, Camille Tlemsani, Benoit Blanchet, et al.
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences
|
July 9, 2011
A simple HPLC-UV method for the simultaneous quantification of gefitinib and erlotinib in human plasma
Lionel Faivre, Charline Gomo, Olivier Mir, et al.
Journal of Pharmaceutical and Biomedical Analysis
|
March 3, 2023
LC-MS/MS method for simultaneous quantification of osilodrostat and metyrapone in human plasma from patients treated for Cushing's Syndrome
David Balakirouchenane, Axelle Vasseur, Fidéline Bonnet-Serrano, et al.
Bulletin Du Cancer
|
October 13, 2018
[Issues of oral targeted therapies in daily clinical practice: 5th edition of the congress of pharmacology of anticancer drugs]
Sonia Zaibet, Charles Vauchier, Nihel Khoudour, et al.
Plos One
|
June 6, 2012
Sarcopenia predicts early dose-limiting toxicities and pharmacokinetics of sorafenib in patients with hepatocellular carcinoma
Olivier Mir, Romain Coriat, Benoit Blanchet, et al.
Pharmacological Research
|
July 6, 2016
Plasma vemurafenib exposure and pre-treatment hepatocyte growth factor level are two factors contributing to the early peripheral lymphocytes depletion in BRAF-mutated melanoma patients
Alicja Puszkiel, Mélanie White-Koning, Nicolas Dupin, et al.
Cancers
|
October 14, 2022
Monitoring of Dabrafenib and Trametinib in Serum and Self-Sampled Capillary Blood in Patients with BRAFV600-Mutant Melanoma
Nora Isberner, Anja Gesierich, David Balakirouchenane, et al.
Page
of 11